Brilaroxazine

Generic Name: Brilaroxazine

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅Cl_₂N_₃O_₃

CAS Number: 1239729-06-6

Unique Ingredient Identifier: X8L60BA01I

Overview

Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.

Background

Indication

Investigated for the treatment of schizophrenia and schizoaffective disorder.

Associated Conditions

No associated conditions information available.

Reviva to Present Long-Term Phase 3 Data for Brilaroxazine in Schizophrenia at SIRS Congress

2 months ago

Reviva Pharmaceuticals will present topline data from the 52-week open-label extension portion of their Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia at the 2025 SIRS Congress in Chicago.

Major Pipeline Expansion in Schizophrenia Treatment: 55+ Companies Developing 60+ Novel Therapies

4 months ago

DelveInsight's latest pipeline report reveals over 55 pharmaceutical companies actively developing 60+ innovative drug candidates for schizophrenia treatment, indicating significant industry investment in addressing this serious mental illness.

Reviva Pharmaceuticals' Brilaroxazine Receives Buy Rating Following Positive Phase 3 Schizophrenia Data

4 months ago

Roth MKM initiated coverage of Reviva Pharmaceuticals with a Buy rating, citing positive Phase 3 data for brilaroxazine in treating schizophrenia.

Schizophrenia Market Set for Strong Growth, Driven by Novel Therapies

5 months ago

The schizophrenia market is expected to grow significantly, driven by the launch of novel therapies and increased diagnosis rates.

Reviva Pharmaceuticals Reports Promising Preliminary OLE Data for Brilaroxazine

5 months ago

Reviva Pharmaceuticals has announced encouraging preliminary data from its Open-Label Extension (OLE) study for brilaroxazine, showing favorable safety, tolerability, and adherence rates. The company is gearing up for its confirmatory Phase III RECOVER-2 trial, with plans to launch in early 2025. Additionally, Reviva has successfully raised $18 million to fund the upcoming trial and support operations until approval.

Drug Development Updates